The current status of biomarkers for predicting toxicity
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: There are significant rates of attrition in drug development. A number of compounds fail to progress past preclinical development due to limited tools that accurately monitor toxicity in preclinical studies and in the clinic. Research has focused on improving tools for the detection of organ-specific toxicity through the identification and characterization of biomarkers of toxicity. AREAS COVERED: This article reviews what we know about emerging biomarkers in toxicology, with a focus on the 2012 Northeast Society of Toxicology meeting titled 'Translational Biomarkers in Toxicology.' The areas covered in this meeting are summarized and include biomarkers of testicular injury and dysfunction, emerging biomarkers of kidney injury and translation of emerging biomarkers from preclinical species to human populations. The authors also provide a discussion about the biomarker qualification process and possible improvements to this process. EXPERT OPINION: There is currently a gap between the scientific work in the development and qualification of novel biomarkers for nonclinical drug safety assessment and how these biomarkers are actually used in drug safety assessment. A clear and efficient path to regulatory acceptance is needed so that breakthroughs in the biomarker toolkit for nonclinical drug safety assessment can be utilized to aid in the drug development process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hazards of heavy metal contamination
Järup, L. (2003) · British Medical Bulletin · doi:10.1093/bmb/ldg032 · Cited by 6,508
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“In general, the current preclinical in vivo models have done quite well in correlating human effect, providing ~ 70% concordance between adverse findings in clinical studies and data generated in preclinical toxicology models [1,2].”
BackgroundCirculating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149 · cited 1×
“Plasma profiles of miRNAs have been used to identify cancers and various organ damage conditions [98-101].”
MethodAre animal models predictive for humans?
Shanks, N., Greek, R., & Greek, J. (2009) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-4-2 · Cited by 677
Adams, R. A., Bauer, J., Flick, M. J., Sikorski, S. L., Nuriel, T., Lassmann, H., Degen, J. L., & Akassoglou, K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061931 · Cited by 335
Muller, P. Y., & Dieterle, F. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903114174 · Cited by 62
Cited by
dos Santos Rodrigues, B., Oue, H., Banerjee, A., Kanekiyo, T., & Singh, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.043 · Cited by 116
Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis
Ippolito, D. L., AbdulHameed, M. D. M., Tawa, G. J., Baer, C. E., Permenter, M. G., McDyre, B. C., Dennis, W. E., Boyle, M. H., Hobbs, C. A., Streicker, M. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfv214 · Cited by 43
Structured Risk Assessment for First-in-Human Studies
van Iersel, M. T., Greenberg, H. E., & Westrick, M. L. (2017) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479017705156 · Cited by 7
“Although reliable safety biomarkers are not available for all organ toxicities, significant advances have been made in identification of biomarkers for toxicity, for instance, testes and liver.(33) There is a tendency to aim for control of a clinical study by using only rule-based stopping criteria.”
Background
Metadata
- Authors
- Campion, S., Aubrecht, J., Boekelheide, K., Brewster, D. W., Vaidya, V. S., Anderson, L., Burt, D., Dere, E., Hwang, K., Pacheco, S., Saikumar, J., Schomaker, S., Sigman, M., & Goodsaid, F.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2013-08-21
- Volume
- 9
- Issue
- 11
- Pages
- 1391-1408
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2042334532
- Cited by
- 97
- References
- 7
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The current status of biomarkers for predicting toxicity. https://app.cochat.ai/papers/10.1517/17425255.2013.827170
- The paper
- Campion, S., Aubrecht, J., Boekelheide, K., Brewster, D. W., Vaidya, V. S., Anderson, L., Burt, D., Dere, E., Hwang, K., Pacheco, S., Saikumar, J., Schomaker, S., Sigman, M., & Goodsaid, F. (2013). The current status of biomarkers for predicting toxicity. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2013.827170
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.